Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to -$133257.0.

  • Abvc Biopharma's Cash from Operations fell 32124.69% to -$133257.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 4760.56%. This contributed to the annual value of -$1.8 million for FY2024, which is 5678.98% up from last year.
  • Per Abvc Biopharma's latest filing, its Cash from Operations stood at -$133257.0 for Q3 2025, which was down 32124.69% from -$894174.0 recorded in Q2 2025.
  • Abvc Biopharma's 5-year Cash from Operations high stood at $60230.0 for Q3 2024, and its period low was -$3.4 million during Q2 2022.
  • Its 5-year average for Cash from Operations is -$1.2 million, with a median of -$899827.0 in 2023.
  • In the last 5 years, Abvc Biopharma's Cash from Operations crashed by 57396.94% in 2021 and then surged by 10443.22% in 2024.
  • Over the past 5 years, Abvc Biopharma's Cash from Operations (Quarter) stood at -$2.5 million in 2021, then soared by 81.74% to -$461069.0 in 2022, then increased by 6.64% to -$430463.0 in 2023, then tumbled by 63.11% to -$702134.0 in 2024, then skyrocketed by 81.02% to -$133257.0 in 2025.
  • Its Cash from Operations stands at -$133257.0 for Q3 2025, versus -$894174.0 for Q2 2025 and -$539833.0 for Q1 2025.